This Article Full Text Full Text (PDF) All Versions of this Article: 49/6/1392    most recent HYPERTENSIONAHA.107.087742v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Omland, T. Articles by de Lemos, J. A. Search for Related Content PubMed PubMed Citation Articles by Omland, T. Articles by de Lemos, J. A. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Related Collections Hypertrophy Epidemiology

(Hypertension. 2007;49:1392.)
© 2007 American Heart Association, Inc.

Original Articles

Plasma Osteoprotegerin Levels in the General Population

Relation to Indices of Left Ventricular Structure and Function

Torbjørn Omland; Mark H. Drazner; Thor Ueland; Moeen Abedin; Sabina A. Murphy; Pål Aukrust; James A. de Lemos

From the Akershus University Hospital (T.O.), Lorenskog, Norway; Research Institute for Internal Medicine, Rikshospitalet (T.U., P.A.), University of Oslo (T.O.), Oslo, Norway; Donald W. Reynolds Cardiovascular Research Center (M.H.D., J.A.d.L.), University of Texas Southwestern Medical Center, Dallas; Division of Cardiology (M.A.), University of Utah Health Sciences Center, Salt Lake City; and Donald W. Reynolds Cardiovascular Research Center (S.A.M.), Brigham and Women’s Hospital, Boston, Mass.

Correspondence to Torbjorn Omland, Department of Medicine, Akershus University Hospital, NO-1478 Oslo, Norway. E-mail torbjorn.omland{at}medisin.uio.no

Osteoprotegerin, a member of the tumor necrosis factor receptor superfamily, has pleiotropic effects on bone metabolism, endocrine function, and the immune system. Myocardial expression and circulating levels of osteoprotegerin are increased in heart failure. The relationship between osteoprotegerin levels in the general population and indices of left ventricular structure and function is unknown. Plasma osteoprotegerin levels and cardiac MRI indices of left ventricular structure and function were available in 2715 subjects (median age: 44 years; 45% male) enrolled in the Dallas Heart Study. The associations between osteoprotegerin concentration and indices of left ventricular structure and function were assessed by linear regression analysis, adjusting for possible confounders. By gender-specific linear regression analysis, higher osteoprotegerin levels were significantly associated with higher left ventricular mass, left ventricular wall thickness, left ventricular concentricity index, and lower left ventricular ejection fraction (P<0.001 for all). After adjustment for age, race, fat-free mass, fat mass, hypertension, diabetes, coronary artery disease, estimated glomerular filtration rate, hypercholesterolemia, smoking status, hormone replacement therapy, coronary artery calcium score >10, and presence of aortic plaque, osteoprotegerin remained significantly associated with each of these left ventricular indices among male subjects (P<0.05 for each). Among female subjects, higher osteoprotegerin was independently associated with higher left ventricular end-systolic volume and lower ejection fraction (P<0.0001 for each) but not with indices of left ventricular hypertrophy. These findings are compatible with the theory that osteoprotegerin may play a pathophysiological role in the development of left ventricular hypertrophy and systolic dysfunction.

Key Words: osteoprotegerin • left ventricular • hypertrophy • hypertension • heart failure

This article has been cited by other articles:

				M. K. Sigrist, A. Levin, L. Er, and C. W. McIntyre Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3157 - 3162. [Abstract] [Full Text] [PDF]

				D. Hofso, T. Ueland, H. Hager, T. Jenssen, J. Bollerslev, K. Godang, P. Aukrust, J. Roislien, and J. Hjelmesaeth Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose Eur. J. Endocrinol., September 1, 2009; 161(3): 451 - 458. [Abstract] [Full Text] [PDF]

				E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]

				T. Omland, T. Ueland, A. M. Jansson, A. Persson, T. Karlsson, C. Smith, J. Herlitz, P. Aukrust, M. Hartford, and K. Caidahl Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 627 - 633. [Abstract] [Full Text] [PDF]